H.C. Wainwright lowered the firm’s price target on ProPhase Labs to $11 from $14 and keeps a Buy rating on the shares. The company reported a sales miss inQ3 but Pharmaloz and Nebula Genomics are expected to drive revenue growth in the coming quarters, the analyst tells investors in a research note. The firm points out that Pharmaloz manufacturing capacity expected to increase 400% by the end of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PRPH:
- ProPhase Labs reports Q3 EPS (30c) vs 6c last year
- ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time
- ProPhase Labs announces growth expectations for Pharmaloz
- ProPhase Labs Announces Substantial Growth Expectations for Pharmaloz Manufacturing Subsidiary due to Skyrocketing Demand for Pharmaloz Output.
- DSS CEO looking forward to ‘significant growth’ for remainder of the year
